SAB 301

Drug Profile

SAB 301

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SAB Biotherapeutics
  • Developer National Institutes of Health (USA)
  • Class Antibodies; Antivirals; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 03 Aug 2017 SAB Biotherapeutics plans a phase II trial for Middle East respiratory syndrome coronavirus
  • 24 Aug 2016 SAB Biotherapeutics receives grant from the Biomedical Advanced Research and Development Authority (BARDA) for SAB 301 development in Middle East respiratory syndrome coronavirus infection
  • 24 May 2016 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top